COMPASS Pathways plc (CMPS)
NASDAQ: CMPS · Real-Time Price · USD
4.160
+0.020 (0.48%)
At close: May 30, 2025, 4:00 PM
4.250
+0.090 (2.16%)
After-hours: May 30, 2025, 6:46 PM EDT
COMPASS Pathways Employees
COMPASS Pathways had 166 employees as of December 31, 2024. The number of employees decreased by 20 or -10.75% compared to the previous year.
Employees
166
Change (1Y)
-20
Growth (1Y)
-10.75%
Revenue / Employee
n/a
Profits / Employee
-$830,114
Market Cap
389.22M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 166 | -20 | -10.75% |
| Dec 31, 2023 | 186 | 5 | 2.76% |
| Dec 31, 2022 | 181 | 65 | 56.03% |
| Dec 31, 2021 | 116 | 54 | 87.10% |
| Dec 31, 2020 | 62 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
CMPS News
- 17 days ago - Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference - Business Wire
- 23 days ago - COMPASS Pathways plc (CMPS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights - Business Wire
- 4 weeks ago - Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities - Business Wire
- 4 weeks ago - Compass Pathways to Announce First Quarter Financial Results on May 8, 2025 - Business Wire
- 5 weeks ago - Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression - Business Wire
- 2 months ago - This Is a Test From GlobeNewswire - GlobeNewsWire
- 2 months ago - Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression - Business Wire